Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma

8 Jan 2008

Abstract excerpt

Interferon-beta (IFN-beta) is a pleiotropic cytokine with antitumoral activity. In an effort to improve the therapeutic index of IFN-beta by providing local, sustained delivery of IFN-beta to gliomas, the safety and biological activity of a human IFN-beta (hIFN-beta)-expressing adenovirus vector (Ad.hIFN-beta) was evaluated in patients with malignant glioma by stereotactic injection, followed 4-8 days later by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18180770
DOI: 10.1038/sj.mt.6300396

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase I Trial of Ad.hIFN-β Gene Therapy for GliomaPMID 18180770Read ↗

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injectionSemantic proximity Read ↗

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.Semantic proximity Read ↗

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerationsSemantic proximity Read ↗

Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trialSemantic proximity Read ↗

A phase I trial investigating the clinical safety and anti-tumor efficacy of a new generation of oncolytic adenovirus, Ad-TD-nsIL12, in Recurrent GlioblastomaSemantic proximity Read ↗

Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastomaSemantic proximity Read ↗

Effect of IFN-β on human glioma cell lines with temozolomide resistanceSemantic proximity Read ↗

Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-α, shows antitumor effect in vitro and in vivoSemantic proximity Read ↗

Low-dose interferon-gamma-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity.Semantic proximity Read ↗

Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovirSemantic proximity Read ↗

lnterferon‐β gene therapy for cancer: Basic research to clinical applicationSemantic proximity Read ↗

Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBMSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.